摘要
目的探讨鼻内窥镜下泪囊鼻腔吻合术联合丝裂霉素C治疗复发性慢性泪囊炎的疗效及安全性。方法选取2018年1月至2019年11月抚州市第一人民医院收治的92例复发性慢性泪囊炎患者作为研究对象。按照随机数字表法将患者分为鼻内镜组和外路组,各46例。将外路组及鼻内镜组又随机分成联合丝裂霉素C治疗和不联合丝裂霉素C治疗,每组23例。外路组患者实行外路鼻腔泪囊吻合术治疗,鼻内镜组患者实施鼻内窥镜下鼻腔泪囊吻合术联合丝裂霉素C治疗。对比两组患者的术后疗效及不良情况。结果鼻内镜组治疗总有效率为95.65%,明显高于外路组(P<0.05)。鼻内镜组术后不良情况总发生率为13.04%,明显低于外路组(P<0.05)。结论鼻内窥镜下泪囊鼻腔吻合术联合丝裂霉素C治疗复发性慢性泪囊炎疗效理想,且安全性高,值得临床推广。
Objective To investigate the efficacy and safety of dacryocystorhinostomy under nasal endoscope combined with mitomycin C in the treatment of recurrent chronic dacryocystitis.Methods 92 eligible patients with recurrent chronic dacryocystitis in First People's Hospital of Fuzhou from January 2018 to November 2019 were selected as the study subjects.According to the random number table,the patients were divided into the endoscopic group and the external group,with 46 cases in each group.The patients in the external group and the endoscopic group were randomly divided into two groups:the group with mitomycin C and the group without mitomycin C,with 23 cases in each group.The patients in the external group were treated with external dacryocystorhinostomy,and the patients in the endoscopic group were treated with endoscopic dacryocystorhinostomy and mitomycin C.The curative effect and adverse condition of the two groups were compared.Results The total effective rate of the endoscopic group was 95.65%,which was significantly higher than that of the external group(P<0.05).The total incidence of postoperative adverse events in the endoscopic group was 13.04%,which was significantly lower than that in the external group(P<0.05).Conclusion Endoscopic dacryocystorhinostomy combined with mitomycin C is effective and safe in the treatment of recurrent chronic dacryocystitis,which is worthy of clinical promotion.
作者
黎乐平
许丽瑶
刘洋
饶裕民
Li Leping;Xu Liyao;Liu Yang;Rao Yumin(Department of Ear-nose-throat,First People's Hospital of Fuzhou,Fuzhou,Jiangxi,344000,China)
出处
《当代医学》
2020年第9期32-35,共4页
Contemporary Medicine
基金
抚州市指导性科技计划项目(抚科计字[2018]20号,第17项)。
